Uveitis refers to inflammation caused in the uvea of the eye. A uvea is the middle layer of the eye that consists of three components namely iris, cilliary body, and the choroid. Uveitis is caused by various factors such as inflammatory diseases, injuries in the eye, microbial infections such as viral, bacterial, and fungal infection or exposure to certain toxic chemicals such as strong acids or pesticides. However, in many cases the cause of this condition remains unknown. It is also found to be effecting people belonging to the age group of 20?50 years. The condition is classified based on the location of inflammation in the uvea and is categorized in three types including anterior uveitis that causes inflammation in the iris and is the most commonly encountered type. The other two types include intermediate uveitis and posterior uveitis that affects the posterior choroid part of the uvea. Uveitis can be treated with the help of various drugs that include corticosteroids, immunosuppressant, monoclonal antibodies, analgesics, and drug formulations.
Myasthenia Gravis Treatment Market Research Report (2019-2026) The latest research report titled, ‘ Global Myasthenia Gravis Treatment Market ‘ has been added by StraitsResearch, which covers the industry overview, market definition, future economic prospects, competition by key players, company profiles, supply (production), and consumption analysis.This intelligence study also provides a comprehensive analysis of the Myasthenia (more…)
AbbVie (NYSE: ABBV) announced today that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.
Globalqyresearch.com has announced the addition of a new research study on the ?GlobalInflammatory Bowel Disease Treatment Market Research Report 2019-2026? to its report database. The report analyzes and forecasts the Inflammatory Bowel Disease Treatment market at global and regional levels. The market has been forecast based on volume (tons) and value (US$ Mn) from 2019 (more…)
Financialnewsmedia.com News Commentary
Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Allergan plc (NYSE: AGN) on behalf of Allergan shareholders concerning the proposed merger with AbbVie Inc.
InvestorsObserver issues critical PriceWatch Alerts for AAPL, ABBV, CSCO, HD, and WFC.
AbbVie Inc. (NYSE: ABBV) and Allergan plc (NYSE: AGN) announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie’s common stock of $78.45 on June 24, 2019.
Myasthenia Gravis Treatment Market Report 2019 StraitsResearch.com published the latest report on Myasthenia Gravis Treatment Market , The report provides details analysis of the market drivers, latest trends and restraints to showcase the current and future market scenario. StraitsResearch has ensured to provide a full- proof report that consists of the market strategies based on (more…)
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on CANOVA (M13-494), a Phase 3 trial evaluating venetoclax (VENCLEXTA® OR VENCLYXTO®) for the investigational treatment of relapsed/refractory multiple myeloma. The CANOVA trial evaluates venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma positive for the translocation (11;14) abnormality. The t(11;14) genetic biomarker is among the most common and routinely tested genetic abnormalities in patients with multiple myeloma.1